CARDIOVASCULAR RISK AND HYPERTENSION (PW de LEEUW and AH GRADMAN, SECTION EDITORS)

Current Hypertension Reports

, Volume 14, Issue 3, pp 183-192

First online:

Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?

  • Vadim TchaikovskiAffiliated withHaemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham
  • , Gregory Y. H. LipAffiliated withHaemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.

Keywords

Angiotensin receptor blockers Hypertension Blood pressure Cancer Tumorigenesis Carcinogenic Antihypertensive therapy Angiotensin Cardiovascular disease Cardiovascular risk Angiotensin-converting enzyme ACE ACE inhibitor Renin-angiotensin system AT1R AT2R Breast cancer Lung cancer